As the COVID-19 pandemic persists, pregnant women have been increasingly affected worldwide. Women during the last trimester of pregnancy are susceptible to severe COVID-19, and there are many challenges towards its treatment. Monoclonal antibody treatment (MAT) is approved for COVID-19 patients to reduce disease severity. However, there are few reports on the MAT in perinatal women. Herein, we report a 39-year-old pregnant female (36 weeks and 6 days of gestation) with improvement in COVID-19 pneumonia after treatment with casiribimab/imdevimab, resulting in successful vaginal delivery (a 2.868 kg male newborn), along with a literature review. Early diagnosis and treatment of pregnant women with COVID-19 are important. Infectious diseases doctors and/or obstetricians should be aware of the MAT option administered to perinatal COVID-19 women to reduce disease severity.
【저자키워드】 COVID-19, lactation, Pregnancy, IL, interleukin, monoclonal antibody treatment, vaginal delivery, LAMP, Loop-mediated isothermal amplification, RT-PCR, Reverse Transcription-Polymerase Chain Reaction, TNF-α, tumor necrosis factor-α, ADA, adalimumab, C&I, casirivimab and imdevimab, ETN, etanercept, IFX, infliximab, MAT, monoclonal antibody treatment, SpO2, percutaneous saturation of oxygen, TARC, thymus and activation-regulated chemokine,